Skip to contentP
Panacea Life Sciences Holdings, Inc.
P
PLSHPanacea Life Sciences Holdings, Inc. Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$324.79K$324.79Kderived−49.7% vs Q4 2021 Net Income-$1.70M-$1.70MderivedN/M vs Q4 2021 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Panacea Life Sciences Holdings, Inc. · CIK 1552189 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$110,789+964.1% Operating Incomederived-$1,375,547N/M Operating Cash Flowderived-$522,999N/M Free Cash Flowderived-$621,842N/M Margins · derivedGross margin34.1%+32.5 pt vs Q4 2021
Operating margin-423.5%−91.0 pt vs Q4 2021
Net margin-524.8%−201.2 pt vs Q4 2021
ended Dec 31, 2022 · filed Mar 30, 2023 · 89 d after period end